1. Home
  2. TWLO vs BIIB Comparison

TWLO vs BIIB Comparison

Compare TWLO & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twilio Inc.

TWLO

Twilio Inc.

HOLD

Current Price

$228.57

Market Cap

36.5B

Sector

Technology

ML Signal

HOLD

Logo Biogen Inc.

BIIB

Biogen Inc.

HOLD

Current Price

$218.12

Market Cap

29.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWLO
BIIB
Founded
2008
1978
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
36.5B
29.9B
IPO Year
2016
1996

Fundamental Metrics

Financial Performance
Metric
TWLO
BIIB
Price
$228.57
$218.12
Analyst Decision
Buy
Buy
Analyst Count
24
25
Target Price
$151.54
$206.83
AVG Volume (30 Days)
1.8M
630.6K
Earning Date
04-30-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
131.82
N/A
EPS
7.29
2.15
Revenue
$399,020,000.00
$9,890,600,000.00
Revenue This Year
$14.44
N/A
Revenue Next Year
$8.21
N/A
P/E Ratio
$31.16
$98.01
Revenue Growth
43.88
2.22
52 Week Low
$98.44
$135.39
52 Week High
$258.35
$225.80

Technical Indicators

Market Signals
Indicator
TWLO
BIIB
Relative Strength Index (RSI) 53.57 51.39
Support Level $215.79 $184.50
Resistance Level $233.85 $219.24
Average True Range (ATR) 8.75 5.27
MACD -1.32 -1.05
Stochastic Oscillator 56.74 38.77

Price Performance

Historical Comparison
TWLO
BIIB

About TWLO Twilio Inc.

Twilio is a cloud-based communications platform-as-a-service company offering communication building blocks that allow for a fully customized customer engagement experience spanning voice, video, chat, and SMS messaging. It does this through various application programming interfaces and prebuilt solution applications aimed at improving customer engagement. The company leverages its Super Network, a global network of carrier relationships, to facilitate high-speed, cost-effective communication.

About BIIB Biogen Inc.

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Share on Social Networks: